HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, July 12, 2022 (HealthDay News) -- Among persons who inject drugs (PWID) with chronic hepatitis C virus (HCV) infection, the proportion in whom HCV RNA was detected decreased from 100 to 48 percent from 2006 to 2019, according to a study published online July 12 in the Annals of Internal Medicine.
Javier A. Cepeda, Ph.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues conducted a community-based, longitudinal cohort study involving 1,323 PWID who were chronically infected with HCV to examine access to all oral HCV treatments and liver disease burden and mortality.
The researchers found that from 2006 to 2019, there was a decrease in the proportion in whom HCV RNA was detected, from 100 to 48 percent. There was a corresponding increase in self-reported treatment, from 3 percent in 2014 to 39 percent in 2019. Across 10,350 valid liver stiffness measures, cirrhosis was detected in 15, 19, and 8 percent of participants in 2006, 2015, and 2019, respectively. There was a significant association seen for undetectable HCV RNA with reduced odds of cirrhosis (adjusted odds ratio, 0.28) and all-cause mortality risk (adjusted hazard ratio, 0.54).
"With continued testing, treatment, and interventions to strengthen linkage to care and prevent HCV transmission, elimination of HCV infection could be achieved within the next decade," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Published on July 12, 2022